Transaction DateRecipientSharesTypePriceValue
26th October 2020Andrew A. F. Hack487,500Grant/award etc.$10.00$4,875,000.00
21st October 2020Timothy B Lowinger1,874Exercise of derivative$3.51$6,577.74
21st October 2020Timothy B Lowinger1,874Open or private sale$17.50$32,795.00
21st October 2020Timothy B Lowinger2,227Open or private sale$17.50$38,972.50
21st October 2020Timothy B Lowinger2,227Exercise of derivative$6.16$13,718.32
20th October 2020Timothy B Lowinger2,227Exercise of derivative$6.16$13,718.32
20th October 2020Timothy B Lowinger2,227Open or private sale$16.74$37,279.98
20th October 2020Timothy B Lowinger15,240Exercise of derivative$1.40$21,336.00
20th October 2020Timothy B Lowinger1,875Exercise of derivative$3.51$6,581.25
20th October 2020Timothy B Lowinger1,611Exercise of derivative$7.43$11,969.73
Mersana Therapeutics
Mersana Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.

Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC)

Ticker: MRSN
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1442836
Employees: 83
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $288 M (0%)
Assets, Current: $295 M (191%)
Property, Plant and Equipment, Net: $2 M (-18%)
Other Assets, Noncurrent: $2 M (0%)
Assets: $311 M (188%)
Long-term Debt, Current Maturities: $2 M (0%)
Accounts Payable, Current: $7 M (-1%)
Accrued Liabilities, Current: $8 M (0%)
Liabilities, Current: $22 M (-6%)
Long-term Debt, Excluding Current Maturities: $3 M (0%)
Other Liabilities, Noncurrent: $225 Th (-18%)
Liabilities: $37 M (26%)
Common Stock, Value, Issued: $7 Th (0%)
Common Stock, Shares, Issued: $68 M (50%)
Additional Paid in Capital, Common Stock: $503 M (0%)
Retained Earnings (Accumulated Deficit): $229 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $2 Th (0%)
Stockholders' Equity (Parent): $274 M (0%)
Liabilities and Equity: $311 M (188%)
Revenue: $796 Th (-1%)
Research and Development: $15 M (-44%)
General and Administrative Expenses: $5 M (-48%)
Other Income, net: $2 Th (-99%)
EPS (basic): $0.33 (0%)
EPS (diluted): $0.33 (0%)